RNS : FOR IMMEDIATE RELEASE

7 MARCH 2016

 

 

 

 

ImmuPharma PLC

 

TR1 NOTIFICATION OF MAJOR INTEREST BY LANSTEAD

 

 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, confirms that it has received a TR-1 by Lanstead Capital LP ("Lanstead") confirming its increased holding in ImmuPharma to 17,893,456 Ordinary Shares.

 

This follows on from the announcement on 1 March 2016 that ImmuPharma has received advance assurance from HM Revenue and Customs of EIS and VCT qualifying status and the issue and allotment of 2,856,539 new Ordinary Shares of 10 pence each.  ImmuPharma now has a total of 121,781,219 Ordinary Shares of 10 pence each in issue which takes Lanstead's current position in the Company to 14.69%

 

Full disclosure of the TR1 is shown below:

1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:					Immupharma plc
2. Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights									x
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):              The placement by ImmuPharma PLC of 2,856,539 new ordinary shares									x
3. Full name of person(s) subject to the notification obligation:				Lanstead Capital LP
4. Full name of shareholder(s) (if different from 3.):
5. Date of the transaction and date on which the threshold is crossed or reached:				4 March 2016
6. Date on which issuer notified:				4 March 2016
7. Threshold(s) that is/are crossed or reached:				15%
8. Notified details:
A: Voting rights attached to shares
Class/type of shares   if possible using the ISIN CODE	Situation previous to the triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares		Number of voting rights		% of voting rights
			Direct		Direct	Indirect	Direct	Indirect
GB0033711010	17,872,341	17,872,341	17,893,456		17,893,456		14.69%

 

 

 

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration date	Exercise/ Conversion Period	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights
N/A

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date	Exercise/ Conversion period	Number of voting rights instrument refers to	% of voting rights
N/A					Nominal	Delta

 

 

Total (A+B+C)
Number of voting rights	Percentage of voting rights
17,893,456	14.69%

 

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

N/A

 

Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:

 

13. Additional information:
14. Contact name:	Lisa De Vargas, Lanstead Partners Limited
15. Contact telephone number:	+1 (801) 895-3700

 

 

 

-Ends-

For further information please contact:   ImmuPharma plc (www.immupharma.org) + 44 (0) 20 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations Twitter: @immupharma           + 44 (0) 7721 413496       Panmure, Gordon & Co., NOMAD & Broker   +44 (0) 20 7886 2500 Fred Walsh, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking

 

 

Notes to Editors

 

ImmuPharma PLC 

 

ImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is led by a commercially focused Board and management team with extensive experience.

 

ImmuPharma announced on 1 March 2016 the successful completion of a £8.4 million fund raise, comprising a Placing and Subscription together with confirmation of EIS and VCT qualifying status. Monies raised will principally be used to complete the pivotal Phase III trial of Lupuzor™. Following the issue of the New Ordinary Shares referred to above, ImmuPharma will have 121,781,219 ordinary shares of 10 pence each (the "Ordinary Shares") in issue.

 

Lupuzor^TM

 

Lupuzor^TM (also referred to as forigerimod, rigerimod, IPP-201101 or P140 is ImmuPharma's lead compound and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune disease. Lupuzor^TM has a novel mechanism of action aimed at modulating the body's immune system so that it does not attack healthy cells, and avoids causing adverse side effects.  It has the potential to halt the progression of the disease in a substantial proportion of patients.

 

Lupuzor^TM has been granted Fast Track status by the US FDA and approval to start Phase III under Special Protocol Assessment (SPA).  This SPA was subsequently amended due to its strong safety and efficacy profile to allow for a reduced number of patients in the pivotal Phase III trial thereby reducing the projected cost and time of development considerably.

 

The pivotal Phase III clinical study is entitled "A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus". It is a pivotal study designed to demonstrate the safety and efficacy of IPP-201101 and as a last step prior to the filing of the drug for approval with the US Food & Drug Administration ("FDA") and the European Medicines Agency ("EMA").  For more information please visit: www.ClinicalTrials.gov/lupuzor

 

 

Commercial Opportunity

There are an estimated five million people globally suffering from Lupus, with approximately 1.5 million patients in the US, Europe and Japan (Source: Lupus Foundation of America). Current 'standard of care' treatments, including steroids and immunosuppressants, can potentially have either serious side effects for patients or limited effectiveness, with over 60% of patients not adequately treated. GSK's Benlysta is the first Lupus drug approved in over 50 years and paves the path to market for Lupuzor™. Based on conservative estimates, and taking into account that Benlysta is priced currently at approximately $35,000 per patient per year, Lupuzor™ would be entering a market with the potential for multi-billion dollar sales. For more information on Lupuzor™ please visit: www.lupuzor.com